Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...

Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment ...

Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.

BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a ...

Follicular thyroid cancer with bone involvement was associated with a significantly elevated risk for brain metastases among women.

(RTTNews) - BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, on Monday announced the resolution of lung metastasis in the first patient treated with Bria-OTS, a ...

Therapeutics announces an unprecedented clinical response including resolution of a lung metastasis with stable disease ...

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS ...

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapy No toxicity related to the treatment; Patient remains on study ...